Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 02, 2015 2:56 AM ET


Company Overview of Constellation Pharmaceuticals, Inc.

Company Overview

Constellation Pharmaceuticals, Inc. discovers and develops drugs in the field of epigenetics. The company discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders, and other diseases. Its pipeline includes bromodomain and extra-terminal proteins that regulate gene expression and small molecule inhibition; and EZH2, a histone lysine methyltransferase that works cooperatively as part of a multi-subunit complex known as PRC2. The company also provides target validation tools; biochemical, biophysical, and cell-based assays; and compound collections against targets in each of the writer, eraser, and reader classes. In addition, its discov...

215 First Street

Suite 200

Cambridge, MA 02142

United States

Founded in 2008





Key Executives for Constellation Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Executive Chairman
Age: 53
Compensation as of Fiscal Year 2015.

Constellation Pharmaceuticals, Inc. Key Developments

Constellation Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Constellation Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Constellation Pharmaceuticals, Inc. Presents at BioFlorida Annual Conference, Oct-13-2014 02:00 PM

Constellation Pharmaceuticals, Inc. Presents at BioFlorida Annual Conference, Oct-13-2014 02:00 PM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Joe Collard, Co-Founder and CEO.

Constellation Pharmaceuticals, Inc. Announces New Preclinical Data on Novel Bet Bromodomain Inhibitors

Constellation Pharmaceuticals, Inc. announced the publication of a study in the Journal of Experimental Medicine demonstrating that small molecule inhibitors selectively targeting BET bromodomains can suppress T helper 17 (T 17) differentiation and T 17-mediated pathology in models of autoimmune diseases. The paper appears in the online early edition of J Exp Med published on October 7, 2013. During the last decade, researchers have uncovered the importance of T 17 cells as an integral part of the immune system that protects the human body from infections. However, this research has also shown that, when pathologically activated, these cells can attack multiple organs in the body and trigger autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Because of the important roles that T 17 cells play in both normal and dysregulated immune function, many academic, biotech and pharmaceutical laboratories have research programs devoted to targeting T 17 cells.

Similar Private Companies By Industry

Company Name Region
North Country Roots, Inc. United States
PharmaNova, Inc. United States
Montigen Pharmaceuticals Inc. United States
Kremers Urban, LLC United States
SOV Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
August 5, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Constellation Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at